Meeting
2022 ASCO Genitourinary Cancers Symposium
BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Benedito A. Carneiro
Brown University, Lifespan Cancer Institute, Providence, RI
Benedito A. Carneiro , Andre DeSouza , Dragan Golijanin , Roxanne Wood , Adam J Olszewski , Sheldon L. Holder , Wafik S. El-Deiry , Rahul Raj Aggarwal , Anthony E. Mega
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04253262
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 128)
DOI
10.1200/JCO.2022.40.6_suppl.128
Abstract #
128
Poster Bd #
G3
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).
First Author: Johann S. De Bono
Poster
2024 ASCO Annual Meeting
PLATIPARP: A phase 2 study of induction docetaxel and carboplatin followed by maintenance rucaparib in treatment of patients with mCRPC with homologous recombination DNA repair deficiency.
First Author: Ruben Raychaudhuri
Poster
2018 Genitourinary Cancers Symposium
TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
First Author: Charles J. Ryan
First Author: Charles J. Ryan